TYK Medicines raises $37M from Qilu, CVG to fund cancer drug trials
What's the deal? Zhejiang Tongyuankang (TYK Medicines) will raise about US$35.1M (roughly $37 million) by issuing 76,000,000 new H shares under a general mandate. Qilu Pharmaceutical is subscribing for 57,000,000 shares and CVG Global for 19,000,000, both at US$0.46 each.
The terms: The price marks a 7.3% discount to the November 12 close of US$0.5. The new shares equal about 20% of existing stock and around 16.7% of the enlarged share base; completion is expected by January 29, 2027.
What's the endgame? TYK is a pre-commercial biopharma developing targeted cancer therapies. The net proceeds back its lead candidate, TY-0540: about US$20.9M for Phase II and III trials in platinum-resistant ovarian cancer, and roughly US$10.5M for trials in CDK4/6-resistant breast cancer. The remaining US$3.51M covers working capital.
Who's in: Qilu is a unit of Hainan-based Qilu Pharmaceutical, a vertically integrated drugmaker. After completion it becomes a substantial shareholder with a 12.5% stake and a six-month lock-up; CVG Global, a Hong Kong fund, takes 4.17% with no lock-up.
Why now? It is TYK's second H-share raise this year aimed at the same drug. In July, it netted about US$55.6M for TY-0540 work. An earlier July subscription agreement with Qilu lapsed in September before this deal was struck.
The signal: Chinese biotechs are tapping Hong Kong placements to fund late-stage research, though at varied scale — Keymed Biosciences netted about US$326.4M in July, while PegBio raised roughly US$9.31M this month. TYK's round reads less as a landmark and more as a continuation of clinical-stage financing, with strategic backing from Qilu as the notable addition.
Read more: sohu.com
Image credit: Generated with Gemini